At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PALI Palisade Bio Inc.
Closed Good Friday 04-17 16:00:00 EDT
0.7199
+0.0196
+2.80%
盘后0.7154
-0.0045-0.63%
19:54 EDT
| High0.7200 | Low0.6900 | Vol46.29K |
| Open0.7003 | D1 Closing0.7003 | Amplitude4.28% |
| Mkt Cap3.17M | Tradable Cap2.94M | Total Shares4.40M |
| T/O32.49K | T/O Rate1.13% | Tradable Shares4.09M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Palisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108
TIPRANKS · 04-09
BRIEF-Palisade Bio Completes Dosing In Phase 1A Portion Of Ongoing Phase 1A/B Study Of Pali-2108
Reuters · 04-09
Palisade Bio Inc - to Report Topline Data From Phase 1a Study by End of May 2025
THOMSON REUTERS · 04-09
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire · 04-09
U.S. RESEARCH ROUNDUP-Ashland, Connectone Bancorp, Neurocrine Biosciences
Reuters · 03-26
Palisade Bio Inc expected to post a loss of $1.99 a share - Earnings Preview
Reuters · 03-21
Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial
MT Newswires Live · 03-14
Palisade Bio: No Serious Adverse Events & No Treatment-Emergent Adverse Events Related to Laboratory Values or Ekgs Seen to Date
THOMSON REUTERS · 03-14
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/B Study of Pali-2108
THOMSON REUTERS · 03-14
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire · 03-14
Palisade Bio Participates in Virtual Investor “What This Means” Segment
GlobeNewswire · 03-04
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
GlobeNewswire · 02-10
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
GlobeNewswire · 01-29
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
GlobeNewswire · 01-22
Palisade Bio Completes All Five Sad Cohorts and Advances to Mad Cohorts of Phase 1a/B Study of Pali-2108 for Treatment of Ulcerative Colitis
THOMSON REUTERS · 01-16
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
GlobeNewswire · 01-16
BRIEF-Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 01-03
Palisade Bio appoints Feagan to Clinical Advisory Board
TIPRANKS · 2024-12-17
Palisade Bio Appoints Brian Feagan, Md, Frcpc, to Its Clinical Advisory Board
THOMSON REUTERS · 2024-12-17
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced at-Market Under Nasdaq Rules
THOMSON REUTERS · 2024-12-12
Introduction
Company Name.
Palisade Bio Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App